Raw sequence reads data from patients with gastric cancer

Profiling somatic mutations in gastric cancer (GC) allows to identify the main driver aberrations and evaluate their clinical and prognostic value. We investigated 77 tumor samples of GC by NGS with the Ion AmpliSeq Ready-to-Use Cancer Hotspot Panel v2 and a custom panel covering six hereditary gastric cancer predisposition genes. Our results confirm that detection of mutations in the main driver genes may have a significant prognostic value for GC patients and provide an independent GC-related set of clinical and molecular genetic data.